Postdoc in Immunology: Senolytics for Fibrosis

BioSpace; San Francisco (CA); Presencial; USD 58.000 - 123.000; Jornada completa

Descripción de la vacante

Lilly seeks a postdoctoral scientist to advance precision senescence biology for fibrotic lung disease. The role spans cellular models, in vivo fibrosis models, and human tissue to pursue a differentiated therapeutic avenue in the senolytics space.

The candidate will work within a high-visibility program, collaborating with academic partners, and will publish findings as first author while developing immune-based strategies to target senescent cells.

Formación

• PhD in a relevant field.
• Experience with cellular senescence and at least one of: fibrosis, aging biology, immunology, therapeutic modality engineering, or relevant analytical approaches.
• Strong publication record.

Responsabilidades

• Establish and characterize models of cellular senescence relevant to fibrotic lung disease using primary human cells, iPSC-derived cells, and in vivo models.
• Identify and validate cell-surface markers distinguishing pathological senescent cells from healthy tissue.
• Develop immune effector-based strategies to selectively eliminate senescent cells in the fibrotic lung.
• Evaluate senolytic efficacy and its impact on fibrosis in human tissue and in vivo models.
• Collaborate with cross-functional teams and external academic partners; present findings at conferences and publish as first author.

Conocimientos

Cellular senescence

Immunology

Single-cell analysis

Proteomics

Fibrosis

Educación

PhD in Immunology, Cell Biology, Molecular Biology, Aging Biology, or closely related field

Descripción del empleo

Lilly seeks a postdoctoral scientist to advance precision senescence biology for fibrotic lung disease. The role spans cellular models, in vivo fibrosis models, and human tissue to pursue a differentiated therapeutic avenue in the senolytics space.

The candidate will work within a high-visibility program, collaborating with academic partners, and will publish findings as first author while developing immune-based strategies to target senescent cells.